Efficacy and safety of once‐weekly dulaglutide in adult <scp>C</scp>hinese patients with type <scp>2</scp> diabetes and lower baseline body mass index

Shi, Yongquan; Liu, Siying; Zhu, Jiankun; Hong, Tianpei

doi:10.1111/1753-0407.13147

Cited by 1 publication

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dulaglutide achieved a greater HbA1c reduction, combined with weight loss and lower risk of hypoglycemia, compared with active comparators (glimepiride and insulin glargine) regardless of baseline HbA1c; patients with a higher baseline HbA1c did achieve greater HbA1c reductions [ 26 ]. In the same Chinese populations, another post-hoc analysis showed that dulaglutide improved glycemic control combined with a slight body weight reduction and low hypoglycemia risk in patients with a BMI < 25 kg/m 2 ; this result suggests that BMI is not a necessary consideration for dulaglutide treatment in Chinese patients with T2DM [ 27 ]. In the present study, baseline HbA1c levels were patient-reported, with a mean value of 8.8% and a mean BMI of 28.1 kg/m 2 ; these values indicate that Chinese diabetologists tend to prescribe dulaglutide for relatively obese patients or for patients with higher HbA1c in real-world clinical practice.…”

Section: Discussionmentioning

confidence: 99%

Study Design and Baseline Characteristics of Patients with T2DM in the Post-marketing Safety Study of Dulaglutide in China (TRUST-CHN)

Guo

et al. 2022

Diabetes Ther

View full text Add to dashboard Cite

Background TRUST-CHN is a prospective, post-marketing safety study in patients with type 2 diabetes mellitus (T2DM) in China to evaluate the safety and effectiveness of dulaglutide in real-world clinical practice. We report here the study design and baseline characteristics of enrolled patients. Methods The study design was described, and baseline data were analyzed, including demographic characteristics, T2DM duration, comorbidities, dulaglutide treatment patterns, and concomitant medications. Results For the present analysis of this ongoing study, data were collected from January 2020 to November 2021. A total of 3313 patients were enrolled, of whom 3294 patients were included in the safety analysis. In total, 1047 patients had a prior history of dulaglutide use before being enrolled in the study. The mean (standard deviation [SD]) age of study subjects was 50.1 (13.2) years, 85.1% were aged < 65 years; 67.9% were male, and 35.9% had an education of university level or higher. Mean (SD) duration of T2DM was 6.4 (6.7) years. Baseline mean (SD) glycated hemoglobin was 8.8% (2.2%), and mean (SD) body mass index was 28.1 (4.1) kg/m 2 . A total of 2867 (87%) patients had at least one comorbidity, the most frequently reported of which were overweight/obesity (87.1%), hyperlipidemia (50.5%), hypertension (47.9%), diabetic neuropathy (18.9%), and coronary artery disease (15.7%). Almost all (99.7%) patients were treated with 1.5 mg dulaglutide; at baseline, 24.8% were treated with this medication as monotherapy and 75.2% in combination therapy with other medications, including metformin (42.3%), sodium glucose co-transporter2 inhibitor (26.7%), insulin (18.3%), α-glucosidase inhibitor (13.1%), sulfonylurea (5.3%), dipeptidyl peptidase 4 inhibitor (4.4%), glucagon-like peptide 1 receptor agonist (2.7%), and thiazolidinedione (2.4%). Conclusion The present analysis revealed real-world baseline characteristics of patients with T2DM in China who use dulaglutide enrolled in TRUST-CHN. These data will enable further exploration of the characteristics of patients with T2DM in China and provide an insight on the current use of dulaglutide in clinical practice. Supplementary Information The online version contains supplementary material available at 10.1007/s13300-022-01268-2.

show abstract

Section: Discussionmentioning

confidence: 99%

Study Design and Baseline Characteristics of Patients with T2DM in the Post-marketing Safety Study of Dulaglutide in China (TRUST-CHN)

Guo

et al. 2022

Diabetes Ther

View full text Add to dashboard Cite

show abstract

Efficacy and safety of once‐weekly dulaglutide in adult Chinese patients with type 2 diabetes and lower baseline body mass index

Cited by 1 publication

References 15 publications

Study Design and Baseline Characteristics of Patients with T2DM in the Post-marketing Safety Study of Dulaglutide in China (TRUST-CHN)

Study Design and Baseline Characteristics of Patients with T2DM in the Post-marketing Safety Study of Dulaglutide in China (TRUST-CHN)

Contact Info

Product

Resources

About